Celularity Inc. Cost of Revenue
Celularity Inc. (CELU) reported Cost of Revenue of $20.07 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-04-30
- Celularity Inc. cost of revenue for the quarter ending 2025-12-31 was $7.37M, a 0.42% increase year-over-year.
- Celularity Inc. cost of revenue for the quarter ending 2025-09-30 was $3.90M, a 0.54% increase year-over-year.
- Celularity Inc. cost of revenue for the quarter ending 2025-06-30 was $5.24M, a 146.91% increase year-over-year.
- Celularity Inc. cost of revenue for the quarter ending 2025-03-31 was $3.55M, a 116.71% increase year-over-year.
- Celularity Inc. cost of revenue for fiscal 2025 was $20.07M, a 33.92% increase from fiscal 2024.
- Celularity Inc. cost of revenue for fiscal 2024 was $14.99M, a 6.41% decline from fiscal 2023.
- Celularity Inc. cost of revenue for fiscal 2023 was $16.02M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | $7.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $11.28M derived: sum of 2 quarters · filed 2026-04-30 | $16.52M derived: sum of 3 quarters · filed 2026-04-30 | $20.07M 10-K · filed 2026-04-30 |
| 2025-09-30 | $3.90M 10-Q · filed 2025-11-14 | $9.15M derived: sum of 2 quarters · filed 2025-11-14 | $12.70M 10-Q · filed 2025-11-14 | $20.04M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | $5.24M 10-Q · filed 2025-08-29 | $8.80M 10-Q · filed 2025-08-29 | $16.14M derived: sum of 3 quarters · filed 2026-04-30 | $20.02M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $3.55M 10-Q · filed 2025-08-29 | $10.90M derived: sum of 2 quarters · filed 2026-04-30 | $14.78M derived: sum of 3 quarters · filed 2026-04-30 | $16.90M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $7.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $11.23M derived: sum of 2 quarters · filed 2026-04-30 | $13.35M derived: sum of 3 quarters · filed 2026-04-30 | $14.99M 10-K · filed 2026-04-30 |
| 2024-09-30 | $3.88M 10-Q · filed 2025-11-14 | $6.01M derived: sum of 2 quarters · filed 2025-11-14 | $7.65M 10-Q · filed 2025-11-14 | $17.25M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.12M 10-Q · filed 2025-08-29 | $3.76M 10-Q · filed 2025-08-29 | $13.37M derived: sum of 3 quarters · filed 2025-08-29 | $16.97M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $1.64M 10-Q · filed 2025-08-29 | $11.25M derived: sum of 2 quarters · filed 2025-08-29 | $14.85M derived: sum of 3 quarters · filed 2025-08-29 | $15.65M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $9.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $13.21M derived: sum of 2 quarters · filed 2025-05-08 | $14.01M derived: sum of 3 quarters · filed 2025-05-08 | $16.02M 10-K · filed 2025-05-08 |
| 2023-09-30 | $3.60M 10-Q · filed 2024-12-06 | $4.40M derived: sum of 2 quarters · filed 2024-12-06 | $6.41M 10-Q · filed 2024-12-06 | |
| 2023-06-30 | $802.00K 10-Q · filed 2024-11-07 | $2.81M 10-Q · filed 2024-11-07 | ||
| 2023-03-31 | $2.00M 10-Q · filed 2024-10-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |